Ivermectin has generated considerable interest as a potential anticancer agent, with laboratory studies suggesting effects on apoptosis, tumor metabolism, autophagy, angiogenesis, cancer stem cells, and multiple cellular signaling pathways. But how much of this evidence comes from cell cultures and animal models, and what has actually been demonstrated in human clinical research?

In this episode of Beyond the Standard Care, we examine peer-reviewed publications exploring ivermectin as a possible anticancer therapy. We discuss the proposed biological mechanisms, the strengths and limitations of the current evidence, why drug repurposing has become an important field in oncology, and the critical distinction between preclinical findings and clinical outcomes.

This conversation is based on published scientific literature and review articles rather than promotional materials or anecdotal reports. The objective is to understand what researchers are investigating, where the evidence is strongest, where uncertainty remains, and which questions future clinical trials will need to answer.

Whether you are a physician, researcher, healthcare professional, student, or simply interested in cancer biology, this episode provides a comprehensive overview of one of the most discussed repurposed drugs in oncology research.